Fibrozumab is a bispecific antibody designed to target both surface integrins at once.
Fibrozumab also targets fibrosis — dissolves fibronectin.
Its Fc domain also activates macrophages, which destroy the antibody-marked cells.
Where other drugs target just one piece of the puzzle, Fibrozumab disrupts all three: both integrins and fibronectin, together, for the first time.
Targeting the resistant tumor microenvironment
EMT Biopharma is developing EMT-601, a preclinical bispecific antibody program designed to address
drug-resistant epithelial cancer and pathological fibrosis through a coordinated therapeutic and diagnostic strategy.
Fibrozumab
Lead bispecific antibody · pre-IND
Two Targets
Integrins anb3 + a5b1
Two Markers
Epithelial cancers and fibrosis
Three Mechanisms
Anti-tumor · Anti-fibrotic · Anti-angiogenic
Development of a human bispecific antibody targeting αvβ3 + α5β1
Fibrozumab targets aggressive, drug-resistant cancer cells
Identification of a “triple-positive” cell population in human lung cancer and PDAC scRNAseq datasets:
- 3 markers: two integrins + one ligand
- Defines cancer cells with high stem/EMT gene signature
- Enriched after treatment with standard of care therapeutics
Fast Track Development Timeline
11 months CLD to IND filing
Early Tox. production strategy.
- CLD Cell Line Development
- cGMP Good Manufacturing Process
- MCB Master Cell Bank
- IND Investigational New Drug
- DS Drug Substance
- DP Drug Product
Leadership
David Cheresh, PhD
Scientific Founder & Director
UCSD Pathology Vice Chair. Developed Unituxin (FDA 2015). TargeGen founder (Fedratinib FDA 2019, $7B exit). 26 issued patents.
Stephen J. McCormack, PhD
CEO & Co-Founder
Veteran biotech operator. Built MannKind ($2B), CytomX ($1.5B), AlleCure (ALK exit), NeuroSystec, Pixium Vision (now Science Corp).
Sara Weis, PhD
VP of Research & Co-Founder
Drives discovery, translational biology, and the Fibrozumab IND-enabling research roadmap.
Kamal Egodage, PhD
Chief Manufacturing Officer
Leads CMC, biologics process development, scale-up and clinical supply for Fibrozumab.
Alfred Atallah, Esq.
General Counsel
Heads corporate, IP, and transactional matters supporting financing, patents, and partnerships.
Doug Frankel
Chief People Officer
Responsible for workforce strategy, recruiting and retaining talent and shaping company.
Advisory Board
Michael Karin, PhD
UCSD / NAS member
Tumor inflammation, fibrosis biology.
Andrew Lowy, MD
UCSD Surgical Oncology
Head of Surgical Oncology, PDAC clinical trials.
Sandip Patel, MD
UCSD Clinical Trials
Clinical Trial Director, lung cancer immune therapy.
Dan Von Hoff, MD
Mayo Clinic, Arizona
World renown Pancreas Cancer physician scientist.
David Brenner, MD
Sanford Burnham Prebys CEO
Liver fibrosis & clinical trials.
David Cheresh, PhD
UCSD Research
Scientific founder — angiogenesis, integrins.